ToxSci Advance Access originally published online on December 22, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences 78, 41-49 (2004)
Copyright © 2004 by the Society of Toxicology
REGULAR ARTICLE |
Modulation of AhR-Mediated CYP1A1 mRNA and EROD Activities by 17ß-Estradiol and Dexamethasone in TCDD-Induced H411E Cells
Institute for Natural Resources and Environmental Management, and Department of Biology, Hong Kong Baptist University, Hong Kong, PR China
1 To whom correspondence should be addressed at Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong. Fax: (852)-3411-5995. E-mail: ckcwong{at}hkbu.edu.hk.
ABSTRACT
TCDD elicits a variety of species- and organ-specific pathological consequences. The differential toxicities are thought to relate to the de novo modulation of TCDD action by endogenous hormones. Previous studies from this laboratory demonstrated a dose- and time-dependent induction of CYP1A1 expression and 7-ethoxyresorufin-O-deethylase (EROD) activities in H4IIE cells by picomolar levels of TCDD treatment. In this study, we examined the hormonal modulation of TCDD-elicited AhR-mediated biochemical responses. Lipid-soluble hormones, 17ß-estradiol (E2), diethylstilbestrol (DES), testosterone (T), 5
-dihydrotestosterone (DHT), dexamethasone (DEX), and T3, were studied for their possible interactions with the TCDD-mediated effects. Our results showed that CYP1A1 expression and EROD activities induced by TCDD were potentiated or suppressed, respectively, by DEX or E2/DES treatment. Other tested hormones, however, had no significant effect. Using a receptor antagonist (RU486), DEX-mediated potentiation of TCDD-elicited EROD activity was completely abolished. E2-mediated suppression, however, was not affected by cotreatment with the estrogen receptor antagonists, 4-hydroxytamoxifen or ICI 182780. Taking a step further to dissect the possible mechanisms involved, with the aid of cycloheximide (CHX), DEX-mediated potentiation was found to depend on the posttranscriptional process. The DEX pretreatment study indicated that the potentiation was a time-dependent process. In contrast, E2-mediated suppression did not rely on the synthesis of protein factors. Presumably it might hinder the formation of the activated TCDD/AhR complex and so the subsequent binding on DRE.
Key Words: CYP1A1 mRNA; EROD; 17ß-estradiol; dexamethasone; H411E cells.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. A. Bielefeld, C. Lee, and D. S. Riddick Regulation of Aryl Hydrocarbon Receptor Expression and Function by Glucocorticoids in Mouse Hepatoma Cells Drug Metab. Dispos., March 1, 2008; 36(3): 543 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shin, N. Wakabayashi, V. Misra, S. Biswal, G. H. Lee, E. S. Agoston, M. Yamamoto, and T. W. Kensler NRF2 Modulates Aryl Hydrocarbon Receptor Signaling: Influence on Adipogenesis Mol. Cell. Biol., October 15, 2007; 27(20): 7188 - 7197. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sonneveld, A. Jonas, O. C. Meijer, A. Brouwer, and B. van der Burg Glucocorticoid-Enhanced Expression of Dioxin Target Genes through Regulation of the Rat Aryl Hydrocarbon Receptor Toxicol. Sci., October 1, 2007; 99(2): 455 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Hu, C. Sorrentino, M. S. Denison, K. Kolaja, and M. R. Fielden Induction of Cyp1a1 Is a Nonspecific Biomarker of Aryl Hydrocarbon Receptor Activation: Results of Large Scale Screening of Pharmaceuticals and Toxicants in Vivo and in Vitro Mol. Pharmacol., June 1, 2007; 71(6): 1475 - 1486. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C Dhulipala, W. V Welshons, and C. S Reddy Cell cycle proteins in normal and chemically induced abnormal secondary palate development: a review Human and Experimental Toxicology, November 1, 2006; 25(11): 675 - 682. [Abstract] [PDF] |
||||




